Transcode Therapeutics (RNAZ) Depreciation & Amortization (CF) (2021 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Depreciation & Amortization (CF) came in at $23936.0 in Q1 2026, up 78.06% YoY from $13443.0 in Q1 2025, and up 231.35% on a QoQ basis from -$18223.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $23936.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 78.06% year-over-year to $23936.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23937.0 (down 66.83% YoY) and the FY2025 annual result came in at $13443.0, down 85.21% from the prior year.
- Depreciation & Amortization (CF) grew to $23936.0 in Q1 2026, from -$18223.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $32354.0 in Q2 2024 to a low of -$18223.0 in Q4 2025.
- A 5-year average of $20609.6 and a median of $23936.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 1622.57% — and 2025, when it sank 276.14%.
- Tracing RNAZ's Depreciation & Amortization (CF) over 5 years: stood at $29505.0 in 2022, then grew by 7.29% to $31655.0 in 2023, then tumbled by 67.32% to $10346.0 in 2024, then slumped by 276.14% to -$18223.0 in 2025, then jumped by 231.35% to $23936.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $23936.0 (Q1 2026), -$18223.0 (Q4 2025), and $4781.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 23,937.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,936.00 |
| Mar 31, 2026 | 23,936.00 |
| Dec 31, 2025 | -18,223.00 |
| Dec 31, 2025 | -18,223.00 |
| Sep 30, 2025 | 4,781.00 |
| Sep 30, 2025 | 4,781.00 |
| Jun 30, 2025 | 13,443.00 |
| Jun 30, 2025 | 13,443.00 |
| Mar 31, 2025 | 13,443.00 |
| Mar 31, 2025 | 13,443.00 |
| Dec 31, 2024 | 10,346.00 |
| Dec 31, 2024 | 10,346.00 |
| Sep 30, 2024 | 16,031.00 |
| Sep 30, 2024 | 16,031.00 |
| Jun 30, 2024 | 32,354.00 |
| Jun 30, 2024 | 32,354.00 |
| Mar 31, 2024 | 32,164.00 |
| Mar 31, 2024 | 32,164.00 |
| Dec 31, 2023 | 31,655.00 |
| Dec 31, 2023 | 31,655.00 |